TABLE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Publication
, Other
Abou-Alfa, GK; Geyer, SM; Nixon, AB; Innocenti, F; Shi, Q; Kumthekar, P; Jacobson, S; El Dika, I; Yaqubie, A; Lopez, J; Huang, B; Tang, Y-W ...
March 7, 2024
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Abou-Alfa, G. K., Geyer, S. M., Nixon, A. B., Innocenti, F., Shi, Q., Kumthekar, P., … Venook, A. P. (2024). TABLE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma. https://doi.org/10.1158/2767-9764.25359894
Abou-Alfa, Ghassan K., Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Priya Kumthekar, Sawyer Jacobson, et al. “TABLE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma,” March 7, 2024. https://doi.org/10.1158/2767-9764.25359894.
Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, et al. TABLE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma. 2024.
Abou-Alfa, Ghassan K., et al. TABLE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma. 7 Mar. 2024. Crossref, doi:10.1158/2767-9764.25359894.
Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, Jacobson S, El Dika I, Yaqubie A, Lopez J, Huang B, Tang Y-W, Wen Y, Schwartz LH, El-Khoueiry AB, Knox JJ, Rajdev L, Bertagnolli MM, Meyerhardt JA, O’Reilly EM, Venook AP. TABLE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma. 2024.